Updated on December 12, 2016
BiologicsMD Announces Patent for Hair Growth Protein
BiologicsMD, a biotechnology start-up out of Fayetville, Arkansas, has recently been granted a patent for a protein named “BMD-2341” that has been said to promote hair growth or prevent hair loss. The patent is titled ““Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone.” This news comes in the latest press release from BiologicsMD.
The research on BMD-2341 seems to be lead by Joshua Sakon, one of four co-inventors of the protein. Joshua Sakon is an associate professor of chemistry and biochemistry at the University or Arkansas. BiologicsMD is also affiliated with the University of Arkansas. This quote from Joshua Sakon seems to imply that the treatment is aimed towards treating alopecia areata and chemotherapy induced hair loss: “Specifically, it could be applied to treat alopecia, a condition in which hair loss occurs in patches on the scalp, or in cases of chemically induced alopecia, which occurs during chemotherapy.” There are also several scientific articles about those subjects listed on the BiologicsMD publications page.
Seems to me if it can regrow hair from chemotherapy-induced loss, it should be able to grow hair anytime. We’ll know a more definitive answer soon enough. Check back to this article for an update.
I’ve just heard back from J. David Owens, CEO of BiologicsMD, via email. Here’s a quote that he approved for me to share on the blog:
“While we have not performed any tests on models of androgenic alopecia, we are hopeful that we can develop BMD-2341 for that indication in the future. The mechanism by which we believe BMD-2341 works is by stimulating the hair follicles into the anagen growth phase via beta-catenin. Androgens have been shown to inhibit beta-catenin, so we are hopeful we could overcome that inhibition. We will certainly keep the community aware of our progress and hopefully will be able to help patients in the coming years.”
We definitely wish BiologicsMD lots of success and expediency in their ventures.